Interindividual variation in olanzapine concentration influenced by UGT1A4 L48V polymorphism in serum and upstream FMO polymorphisms in cerebrospinal fluid

Journal of Clinical Psychopharmacology

Volumn 32, Issue 2, 2012, Pages 287-289

  Mao, Mao ^a   Skogh, Elisabeth ^b   Scordo, Maria Gabriella ^a   Dahl, Marja Liisa ^c  

^a UPPSALA UNIVERSITY   (Sweden)

^b LINKÖPING UNIVERSITY   (Sweden)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

4' N DESMETHYL OLANZAPINE; DIMETHYLANILINE MONOOXYGENASE; FMO1 PROTEIN; FMO3 PROTEIN; GLUCURONOSYLTRANSFERASE 1A4; OLANZAPINE; UNCLASSIFIED DRUG;

ADULT; CEREBROSPINAL FLUID; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG BLOOD LEVEL; FEMALE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HAPLOTYPE; HUMAN; INTRON; LETTER; MALE; PHARMACOGENETICS; PRIORITY JOURNAL; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SMOKING; STEADY STATE; TREATMENT DURATION;

ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; CYTOCHROME P-450 CYP1A2; CYTOCHROME P-450 CYP2D6; FEMALE; HUMANS; MALE; PIRENZEPINE; PSYCHOTIC DISORDERS; SCHIZOPHRENIA; SMOKING; WEIGHT GAIN;

EID: 84857803788     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0b013e31824997a8     Document Type: Letter

References (15)

1. Melkersson KI, Dahl ML. Relationship between levels of insulin or triglycerides and serum concentrations of the atypical antipsychotics clozapine and olanzapine in patients on treatment with therapeutic doses. Psychopharmacology (Berl). 2003;170:157-166. (Pubitemid 37421527)
2. Perry PJ, Argo TR, Carnahan RM, et al. The association of weight gain and olanzapine plasma concentrations. J Clin Psychopharmacol. 2005;25:250-254. (Pubitemid 40685789)
3. Skogh E, Sjodin I, Josefsson M, et al. High correlation between serum and cerebrospinal fluid olanzapine concentrations in patients with schizophrenia or schizoaffective disorder medicating with oral olanzapine as the only antipsychotic drug. J Clin Psychopharmacol. 2011;31:4-9.
4. Carrillo JA, Herraiz AG, Ramos SI, et al. Role of the smoking-induced cytochrome P450 (CYP)1A2 and polymorphic CYP2D6 in steady-state concentration of olanzapine. J Clin Psychopharmacol. 2003;23:119-127. (Pubitemid 36368788)
5. Ghotbi R, Mannheimer B, Aklillu E, et al. Carriers of the UGT1A4 142T9G gene variant are predisposed to reduced olanzapine exposureVan impact similar to male gender or smoking in schizophrenic patients. Eur J Clin Pharmacol. 2010;66:465-474.
6. Laika B, Leucht S, Heres S, et al. Pharmacogenetics and olanzapine treatment: CYP1A2*1F and serotonergic polymorphisms influence therapeutic outcome. Pharmacogenomics J. 2010;10:20-29.
7. Nozawa M, Ohnuma T, Matsubara Y, et al. The relationship between the response of clinical symptoms and plasma olanzapine concentration, based on pharmacogenetics: Juntendo University Schizophrenia Projects (JUSP). Ther Drug Monit. 2008;30:35-40. (Pubitemid 351161096)
8. Linnet K. Glucuronidation of olanzapine by cDNA-expressed human UDP-glucuronosyltransferases and human liver microsomes. Hum Psychopharmacol. 2002;17:233-238. (Pubitemid 34823349)
9. Ring BJ, Catlow J, Lindsay TJ, et al. Identification of the human cytochromes P450 responsible for the in vitro formation of the major oxidative metabolites of the antipsychotic agent olanzapine. J Pharmacol Exp Ther. 1996;276:658-666. (Pubitemid 126660505)
10. Erichsen TJ, Ehmer U, Kalthoff S, et al. Genetic variability of aryl hydrocarbon receptor (AhR)Ymediated regulation of the human UDP glucuronosyltransferase (UGT) 1A4 gene. Toxicol Appl Pharmacol. 2008;230:252-260.
11. Krueger SK, Williams DE. Mammalian flavin-containing monooxygenases: structure/function, genetic polymorphisms and role in drug metabolism. Pharmacol Ther. 2005;106:357-387. (Pubitemid 40726294)
12. Hines RN, Luo Z, Hopp KA, et al. Genetic variability at the human FMO1 locus: significance of a basal promoter yin yang 1 element polymorphism (FMO1*6). J Pharmacol Exp Ther. 2003;306:1210-1218. (Pubitemid 37025332)
13. Koukouritaki SB, Poch MT, Cabacungan ET, et al. Discovery of novel flavin-containing monooxygenase 3 (FMO3) single nucleotide polymorphisms and functional analysis of upstream haplotype variants. Mol Pharmacol. 2005;68:383-392. (Pubitemid 41058302)
14. King CD, Rios GR, Assouline JA, et al. Expression of UDP- glucuronosyltransferases (UGTs) 2B7 and 1A6 in the human brain and identification of 5-hydroxytryptamine as a substrate. Arch Biochem Biophys. 1999;365:156-162. (Pubitemid 29394261)
15. Zhang J, Cashman JR. Quantitative analysis of FMO gene mRNA levels in human tissues. Drug Metab Dispos. 2006;34:19-26. (Pubitemid 43042642)